Dear Colleagues,

Since the first half of the 20th century, nuclear medicine departments have provided thyroid cancer treatment with radioactive iodine (I-131), making it the first true theranostic pair.

Until about the first decade of the 2000s, only a few radiopharmaceuticals were introduced in the treatment of cancer, often only for palliative purposes, thereafter the field started to rapidly expand with the urgent need to establish and develop new theranostic centers.

New challenges are emerging:

1. New nuclides, with particular attention for the alpha emitters, linked to new ligand with greater affinity for their receptors by virtually simulating their interactions
2. A new dosimetric approach at cellular and subcellular level to allow dose modifications and personalized dosimetry, guided by theranostic pair.
3. For several times, TRT (Targeted Radionuclide Therapy) has been the last choice in cancer treatment. In the light of the most recent clinical experience, TRT combined with the traditional therapy might be able to improve the clinical outcome. In addition, clinical trials are desirable that can validate the role of TRT as first-line therapy and as a replacement of conventional chemotherapy.

We cordially invite authors to submit original research or review articles pertaining to this important and fast-progressing field of medicine and not only strictly related to the above items.